Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bayer AG has initiated an observational study titled ‘Drug Utilization Study for Eylea 40 mg/mL Using the PICLEO Paediatric Dosing Device in Preterm Infants With Retinopathy of Prematurity in the UK.’ The study aims to gather data on the use of aflibercept (Eylea) in preterm infants with retinopathy of prematurity (ROP) using a pediatric dosing device. This research is significant as it seeks to determine the prevalence of aflibercept use in the UK and assess the feasibility of a long-term safety study.
The intervention being tested is aflibercept, marketed as Eylea, which is administered via a prefilled syringe using the PICLEO pediatric dosing device. Aflibercept is designed to inhibit abnormal blood vessel growth in the retina by blocking the vascular endothelial growth factor (VEGF).
The study follows an observational cohort model with a cross-sectional time perspective. It does not involve any direct interventions or patient visits, as it relies on data from the National Neonatal Research Database.
The study began on March 5, 2024, with primary completion expected by March 2025, contingent on the number of cases identified. The last update was submitted on August 6, 2025. These timelines are crucial for tracking the study’s progress and potential future research.
This study could influence Bayer’s stock performance by potentially expanding the use of Eylea in a new demographic, thus impacting investor sentiment positively. The study’s outcome might also affect the competitive landscape in the treatment of ROP.
The study is currently recruiting, with further details available on the ClinicalTrials portal.